iLABMED最新文献

{"title":"RT-PCR in the early detection and monitoring of pathogen residual status in neonatal bacterial meningitis","authors":"Ying Li,&nbsp;Ruiqi Xiao,&nbsp;Peicen Zou,&nbsp;Yue Du,&nbsp;Qinglin Lu,&nbsp;Jun Cui,&nbsp;Yajuan Wang","doi":"10.1002/ila2.55","DOIUrl":"10.1002/ila2.55","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Early identification of pathogenic bacteria and monitoring residual status are essential for accurate treatment of neonatal bacterial meningitis (NBM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Clinical data and specimens were collected from neonates with NBM. Bacterial cultures and RT-PCR of blood and cerebrospinal fluid (CSF) were compared to assess the positivity rate, sensitivity and specificity of each method.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>RT-PCR had a higher positivity rate compared with cultures, regardless of whether antibiotics had been used prior to specimen collection. After 1 week of regular antibiotic treatment, the number of pathogen DNA copy numbers in CSF was either undetectable or significantly reduced compared with previous levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>RT-PCR is expected to provide a basis for the precise application of antibiotics and the course of treatment for NBM, particularly in patients with negative cultures or those who have already been treated with antibiotics.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 4","pages":"307-315"},"PeriodicalIF":0.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.55","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141929178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid development of neurological infection in a patient with human immunodeficiency virus following schistosomiasis: A case report","authors":"Yan Liu,&nbsp;Guoqiang Zhou,&nbsp;Wei Jiang,&nbsp;Xianglong Kong","doi":"10.1002/ila2.54","DOIUrl":"10.1002/ila2.54","url":null,"abstract":"<p>HIV-1 and schistosomal infections present significant global health challenges, and neurological manifestations of these pathogens are easily misdiagnosed due to their rarity. Here, we report the case of a 36-year-old patient with acquired immunodeficiency syndrome who was initially diagnosed with human immunodeficiency virus-1 (HIV-1) infection 4 years earlier, although untreated for approximately 3 years until he began antiretroviral therapy (ART) following a tuberculosis diagnosis and hospitalization. Despite achieving virological suppression of HIV-1 1 year after ART, he was readmitted with high fever and headache. Initial therapy for suspected tuberculosis based on clinical performance and brain imaging features failed, and further investigation confirmed an intracranial infection caused by schistosomiasis. Following anti-schistosomal treatment and optimized ART, the patient recovered fully and was discharged. This case of a patient in Asia infected with human immunodeficiency virus (HIV) who rapidly developed a neurological infection subsequent to acquiring schistosomiasis highlights the need for awareness of such coinfections in patients with HIV.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 4","pages":"316-322"},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.54","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141814788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “The exploration of cell population data in clinical use: Beyond infectious diseases”","authors":"","doi":"10.1002/ila2.53","DOIUrl":"10.1002/ila2.53","url":null,"abstract":"<p>Huang S, Liu Y, Qian L, Zhou J, Wang D. The exploration of cell population data in clinical use: beyond infectious diseases. iLABMED. 2024;2(2):125–40.</p><p>In the last paragraph of the “3.2.2 COVID-19” section, the text “(mean lymphocyte volume [LV] x LV − SD)/(mean lymphocyte conductivity [LC])” was incorrect. This should have read: “(mean lymphocyte volume [LV] × LV − SD)/(mean lymphocyte conductivity [LC])”.</p><p>In paragraph 5 of the “3.2.3 Other infectious diseases” section and Table 1, the texts “95% <i>Cl</i>” was incorrect. These should have read: “95% <i>CI</i>”.</p><p>We apologize for these errors.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 3","pages":"226"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.53","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141831344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dye-based recombinase-aided amplification assay with enhanced sensitivity and specificity","authors":"Zijin Zhao,&nbsp;Yanbo You,&nbsp;Shaowei Hua,&nbsp;Xinxin Shen,&nbsp;Lingjun Li,&nbsp;Xuejun Ma","doi":"10.1002/ila2.51","DOIUrl":"10.1002/ila2.51","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Fluorescent recombinase-aided amplification (RAA) assays are increasingly being used in the detection of a variety of pathogens and have the advantages of rapidity and simplicity and similar sensitivity and specificity, compared with real-time PCR (qPCR) assays, but they require a complex probe design. To eliminate the addition of fluorescent probes for RAA, an EvaGreen dye-based recombinase-aided amplification (EvaGreen-RAA) assay using self-avoiding molecular recognition system (SAMRS) primers was developed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The SAMRS primers effectively avoided the production of primer dimers, thus improving the detection sensitivity, while EvaGreen dye was used to quantitatively measure the amplified products in real time. Using <i>Staphylococcus aureus</i> (SA) and <i>Listeria monocytogenes</i> (LM) as examples, EvaGreen-RAA with SAMRS primers was developed. As a reference and comparison, a traditional fluorescence probe RAA method and a RAA with SAMRS primers (SAMRS-RAA) for detecting SA and LM were also investigated. Serial dilutions of recombinant plasmids were used to evaluate the sensitivity of the assays. Unenriched and enriched simulated milk samples were used to evaluate the limits of detection (LOD) of these methods. Using high-resolution melting (HRM) was used to explore the sensitivity of the dual EvaGreen-RAA assay.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The sensitivity of the fluorescent RAA method for detecting SA and LM was 10 copies/μL using plasmids and the sensitivity of the SAMRS-RAA and EvaGreen-RAA for detecting SA and LM plasmids was 1 copies/μL. The LOD values of the EvaGreen-RAA for SA and LM in unenriched simulated milk samples were 100 and 50 CFU/mL, respectively, and the LOD value for both SA and LM using enriched simulated milk samples was 10 CFU/mL. EvaGreen-RAA had linear amplification in real time in the range of 1–10⁵ copies/μL of the plasmids of SA and LM. The sensitivity of the dual EvaGreen-RAA assay for SA and LM was estimated to be 10² CFU/mL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A real-time quantitative EvaGreen-RAA method for detecting SA and LM was developed, which eliminates the need to design complex RAA probes. This dye-based RAA with SARMS primers provides a new strategy for simplifying fluorescence probe RAA and allowing the detection of multiple pathogens, which has many potential applications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 4","pages":"294-306"},"PeriodicalIF":0.0,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.51","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141650395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A predictive model for ischemic colitis: Integrating clinical and laboratory parameters","authors":"Chonghui Hu,&nbsp;Xiuying Zhao,&nbsp;Bo Jiang,&nbsp;Xuan Jiang,&nbsp;Yutang Ren,&nbsp;Jiaojiao Guo","doi":"10.1002/ila2.52","DOIUrl":"10.1002/ila2.52","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>We aimed to develop a predictive model for the clinical diagnosis of ischemic colitis (IC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Clinical data were collected from patients with acute IC lesions who were diagnosed and admitted to Beijing Tsinghua Changgung Hospital from January 2016 to December 2022. These patients were included in the IC case group in this retrospective observational study. The control group comprised patients aged ≥40 years who were diagnosed with abdominal pain during the same period, excluding those with IC. All patients were divided into a training and test sets based on the time window. Least absolute shrinkage and selection operator regression was used to screen risk factors for the occurrence of IC. Logistic stepwise regression (maximum likelihood ratio method) was performed in multifactorial analysis, and a diagnostic prediction model for IC was established using R language. The area under the receiver operating characteristic (ROC) curve (AUC) was examined to assess differentiation using working ROC curves. We used bootstrap resampling (1000 times) for internal validation. Model calibration curves and decision curve analysis (DCA) were also applied.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our study indicates that constipation, hematochezia, neutrophil counts, and specific abdominal computed tomography (CT) (plain scan) findings, including intestinal wall edema and thickening, intestinal lumen stenosis, and dilation, are independent predictors of IC. The predictive model exhibited high discriminative ability with an AUC of 0.9788 in the training set, and the calibration and DCA curves demonstrated excellent model performance. After validation, the AUC remained robust at 0.9868, underscoring the model's reliability in predicting IC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>According to our model, constipation accompanied by hematochezia necessitates careful consideration of IC. Abdominal CT (plain scan) is an effective diagnostic tool for IC, and it is common for patients to exhibit elevated neutrophil counts. The predictive model, demonstrating high discriminative ability and accuracy, shows promise for practical application in clinical settings, aiding in the early diagnosis and management of IC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 3","pages":"157-167"},"PeriodicalIF":0.0,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.52","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141649614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy evaluation of Roche Accu-Chek Performa blood glucose meters at low glucose concentrations: A nine-year retrospective study","authors":"Zhipeng Zhao,&nbsp;Runqing Li,&nbsp;Xiuying Zhao,&nbsp;Lina Zhang,&nbsp;Tengjiao Wang,&nbsp;Song Yang,&nbsp;Ning Han,&nbsp;Dong Zhu","doi":"10.1002/ila2.49","DOIUrl":"https://doi.org/10.1002/ila2.49","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the accuracy of Roche Accu-Chek Performa glucose meters at a low glucose concentration of &lt;5.55 mmol/L (100 mg/dL) over a 9-year period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The accuracy of the Roche Accu-Chek Performa glucose meters at low glucose concentrations was evaluated using annual comparison data for 9 consecutive years from 2015 to 2023, according to the acceptability criteria specified in International Organization for Standardization (ISO) 15197:2013. Blood samples with low glucose concentrations of &lt;5.55 mmol/L were prepared by incubation and glycolysis. The glucose concentration was detected using Roche Accu-Chek Performa glucose meters and a biochemical analyzer in the central laboratory.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 2978 pairs of comparison results from 211 glucose meters at a low glucose concentration of &lt;5.55 mmol/L were retrospectively analyzed from 2015 to 2023. The clinical use duration spanned from 1 to 9 years and 40.76% (86 out of 211 glucose meters) had been used for more than 2 years. The correlation coefficient <i>r</i> between glucose meter measurements and laboratory reference values was 0.98 (<i>p</i> &lt; 0.001). The mean according to Roche Accu-Chek Performa glucose meters was 0.05 mmol/L (0.9 mg/dL) higher than that of the biochemical analyzer (<i>Z</i> = −13.82, <i>p</i> &lt; 0.0001). The results showed that 100.00% (211 out of 211) of the Roche Accu-Chek Performa glucose meters met the acceptability criteria specified in ISO 15197:2013. At a low glucose concentration of &lt;5.55 mmol/L, 99.90% (2975 out of 2978) of the comparative data pairs in the error distribution fell within the range of ±0.83 mmol/L (15 mg/dL). Parkes consensus error grid analysis showed that 100.00% (2978 out of 2978) of comparative data pairs fell within region A.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study demonstrated that Roche Accu-Chek Performa glucose meters successfully met the accuracy standards of ISO 15197:2013 for measuring blood glucose within the hypoglycemic range. Greater attention should be given to the performance of blood glucose monitoring systems in the low glycemic range, especially for patients with diabetes who are prone to hypoglycemia and require precise measurements.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 3","pages":"141-148"},"PeriodicalIF":0.0,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.49","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142404804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of central nervous system infection with Scedosporium boydii","authors":"Zhen Cai,&nbsp;Dongchao Pan,&nbsp;Ronghua Geng,&nbsp;Jidi Fu,&nbsp;Fen Qu","doi":"10.1002/ila2.48","DOIUrl":"10.1002/ila2.48","url":null,"abstract":"<p><i>Scedosporium boydii</i> is considered an opportunist fungal pathogen in immunocompromised patients. It also causes serious and fatal central nervous system infections. In this study, a man with brain abscesses infected with <i>S</i>. <i>boydii</i> was diagnosed using multiple methods, including microscopy, culture combined with Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MOLDI-TOF MS), internal transcribed spacer sequencing and Metagenomic next-generation sequencing (mNGS). This successful diagnosis highlights the importance of using a variety of techniques to identify and treat infections caused by this dangerous fungus.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 3","pages":"221-225"},"PeriodicalIF":0.0,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.48","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141359769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypermethylation of GSTM5 and its effect on oxidation in myelodysplastic syndrome","authors":"Chi Wang,&nbsp;Yafei Yu,&nbsp;Qing Chang,&nbsp;Tengteng Dong,&nbsp;Liye Wang,&nbsp;Mianyang Li","doi":"10.1002/ila2.47","DOIUrl":"10.1002/ila2.47","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hypermethylation of glutathione-S-transferase 5 (<i>GSTM5</i>) and its effect on oxidation in the pathogenesis of myelodysplastic syndrome (MDS) were investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p><i>GSTM5</i> methylation was detected in bone marrow (BM) samples from MDS patients, acute myeloid leukemia (AML) patients, and control individuals using methylation-specific PCR and MassARRAY analysis. Bisulfite sequencing PCR was performed to verify methylation levels, while mRNA levels were determined using reverse transcription polymerase chain reaction. Correlations between <i>GSTM5</i> methylation and clinical parameters were analyzed. The MDS cell line, SKM-1, was treated with decitabine, buthionine sulfoximine, or overexpression of <i>GSTM5</i>, and the glutathione level and cell viability were detected.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The MassARRAY analysis revealed significant differences in <i>GSTM5</i> methylation levels between the MDS and control groups. <i>GSTM5</i> methylation levels were significantly increased in the high-risk subgroup and showed a significant association with MDS progression to AML (hazard ratio = 3.6). Levels of <i>GSTM5</i> mRNA were significantly decreased in the MDS group, exhibiting a negative correlation with the <i>GSTM5</i> gene methylation level. Normal BM HS-5 cells exhibited significantly lower levels of <i>GSTM5</i> methylation than SKM-1 cells. Overexpression of <i>GSTM5</i> in SKM-1 cells or treatment with buthionine sulfoximine or decitabine resulted in inhibition of proliferation and significantly decreased glutathione levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p><i>GSTM5</i> plays an anti-oxidative role in MDS and the tumor suppressor effect of <i>GSTM5</i> may be mediated by reducing glutathione levels. <i>GSTM5</i> hypermethylation and low levels of <i>GSTM5</i> expression may be prognostic markers for MDS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 2","pages":"108-124"},"PeriodicalIF":0.0,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.47","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141357612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the divide: Harmonizing polarized clinical laboratory medicine practices","authors":"Yi-Wei Tang,&nbsp;Joseph D. Yao","doi":"10.1002/ila2.46","DOIUrl":"https://doi.org/10.1002/ila2.46","url":null,"abstract":"<p>In today's healthcare, clinical laboratory medicine stands as a cornerstone of patient care, providing vital diagnostic insights that inform decisions in disease management. Yet, within this crucial field, a dichotomy persists between two predominant models of laboratory testing to support clinical practice: point-of-care testing (PoCT) and central laboratory testing [<span>1</span>]. This schism, while born of practical necessity and evolving technology, presents both opportunities and challenges that warrant closer examination.</p><p>Point-of-care testing, characterized by its immediacy and accessibility, offers rapid results at or near the patient's location, facilitating swift clinical interventions and enhancing patient satisfaction [<span>2</span>]. Devices used for PoCT are often compact and portable, enabling testing in diverse settings, from emergency departments to remote clinics [<span>3</span>]. This model provides healthcare providers with real-time data to make timely care decision, as a result of reducing the time to diagnosis and treatment initiation.</p><p>Conversely, central laboratory testing operates on a larger scale, often in dedicated facilities equipped with advanced instrumentation and automation. Central clinical laboratories boast a wide menu of tests, offering comprehensive diagnostic capabilities that encompass a spectrum of medical specialties. Standardization and quality control measures are rigorously enforced, ensuring the sensitivity, reliability, and accuracy of test results. Furthermore, central laboratories facilitate economies of scale, driving down costs and promoting efficiency in resource utilization.</p><p>However, this division between PoCT and central laboratory testing has fostered challenges in interoperability, data management, and standardization. Integration of PoCT results into electronic health records (EHR) remains a significant hurdle, limiting the seamless exchange of clinical data across different care settings [<span>4</span>]. In addition, differences in testing methods and quality assurance protocols between PoCT devices and central laboratory assays may introduce discrepancies in results and interpretation of results, posing risks to patient safety and clinical decision-making.</p><p>Yet, amidst these challenges, there exists a growing recognition of the need for synergy between PoCT and central laboratory testing. Collaborative efforts are underway to bridge the gap, leveraging technological innovations to enhance connectivity, streamlining data exchange, and harmonizing testing methods across different care settings. Interoperable EHR systems and middleware solutions are facilitating the seamless integration of PoCT results into central laboratory databases and EHR, fostering an integrated approach to patient care.</p><p>Furthermore, advancements in point-of-care technologies, such as lab-on-a-chip devices, hand-held devices, and mobile phone applications, hold promise in expanding t","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 2","pages":"67-69"},"PeriodicalIF":0.0,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.46","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141435642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The exploration of cell population data in clinical use: Beyond infectious diseases","authors":"Shayuanzi Huang,&nbsp;Yin Liu,&nbsp;Liu Qian,&nbsp;Juan Zhou,&nbsp;Dong Wang","doi":"10.1002/ila2.41","DOIUrl":"10.1002/ila2.41","url":null,"abstract":"<p>Cell population data (CPD) is regarded as the fingerprint of a blood cell at a given moment. CPD parameters harbor information associated with cell morphology and can be automatically generated using modern hematological analyzers. Various studies have revealed many unique clinical applications for CPD, especially for infectious diseases, such as sepsis. For example, one monocyte-related CPD parameter is the monocyte distribution width (MDW), which can be generated using a Beckman Coulter hematological analyzer. MDW has received FDA and CE approval for aiding in sepsis diagnosis in adult patients in the emergency department. Additionally, MDW can serve as a diagnostic biomarker in patients infected with SARS-CoV-2. CPD has also been widely explored for possible clinical applications beyond infectious diseases, such as for predicting myelodysplastic syndromes, screening for hematological malignancies, and detecting sterile inflammation. CPD parameter measurements are easily obtained and quite cost-effective, making them practical for clinical use. However, there are some potential drawbacks of CPD parameters. Some pre-analytical conditions can affect CPD values. Furthermore, CPD are specific to certain hematological analyzers and the result cannot be transferred between different analyzers. The practical usefulness of CPD reference intervals is also still questionable. In this review, wesummarize the current studies related to CPD and its clinical applications. Additional well-designed clinical studies related to CPD are still expected.</p>","PeriodicalId":100656,"journal":{"name":"iLABMED","volume":"2 2","pages":"125-140"},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ila2.41","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141123160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}